Design, syntheses, and characterization of pharmacophore based chemokine receptor CCR5 antagonists as anti prostate cancer agents

European Journal of Medicinal Chemistry

Volumn 69, Issue , 2013, Pages 647-658

  Arnatt, Christopher K ^a   Zaidi, Saheem A ^a   Zhang, Zhu ^b   Li, Guo ^a   Richardson, Amanda C ^a   Ware, Joy L ^a,c   Zhang, Yan ^a,c  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^b TIANJIN MEDICAL UNIVERSITY   (China)

^c VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

CCR5 antagonist; Pharmacophore based molecular design; Prostate cancer

Indexed keywords

ANTINEOPLASTIC AGENT; CHEMOKINE RECEPTOR CCR5 ANTAGONIST; N [5 [1 (4 ACETAMIDOBENZYL)PIPERIDIN 4 YL] 2 ETHOXYPHENYL]BENZAMIDE; N [5 [1 (4 ACETAMIDOBENZYL)PIPERIDIN 4 YL] 2 ETHOXYPHENYL]PYRAZINE 2 CARBOXAMIDE; N [5 [1 (4 AMINOBENZYL)PIPERIDIN 4 YL] 2 ETHOXYPHENYL]PYRAZINE 2 CARBOXAMIDE; N [5 [1 (4 AMINOBENZYL)PIPERIDIN 4 YL] 2 METHOXYPHENYL]PYRAZINE 2 CARBOXAMIDE; N [5 [1 (4 NITROBENZYL)PIPERIDIN 4 YL] 2 ETHOXYPHENYL]BENZAMIDE; N [5 [1 (4 NITROBENZYL)PIPERIDIN 4 YL] 2 ETHOXYPHENYL]PYRAZINE 2 CARBOXAMIDE; N [5 [1 (4 NITROBENZYL)PIPERIDIN 4 YL] 2 ISOPROPOXYPHENYL]BENZAMIDE; N [5 [1 (4 NITROBENZYL)PIPERIDIN 4 YL] 2 ISOPROPOXYPHENYL]PYRAZINE 2 CARBOXAMIDE; N [5 [1 (4 NITROBENZYL)PIPERIDIN 4 YL] 2 METHOXYPHENYL]BENZAMIDE; N [5 [1 (4 NITROBENZYL)PIPERIDIN 4 YL] 2 METHOXYPHENYL]PYRAZINE 2 CARBOXAMIDE; N [5 [1 [4 (DIETHYLAMINO)BENZYL]PIPERIDIN 4 YL] 2 ETHOXYPHENYL]BENZAMIDE; N [5 [1 [4 (DIETHYLAMINO)BENZYL]PIPERIDIN 4 YL] 2 ETHOXYPHENYL]PYRAZINE 2 CARBOXAMIDE; N [5 [1 [4 (DIETHYLAMINO)BENZYL]PIPERIDIN 4 YL] 2 ISOPROPOXY]PHENYL]BENZAMIDE; N [5 [1 [4 (DIETHYLAMINO)BENZYL]PIPERIDIN 4 YL] 2 ISOPROPOXYPHENYL]PYRAZINE 2 CARBOXAMIDE; N [5 [1 [4 (DIETHYLAMINO)BENZYL]PIPERIDIN 4 YL] 2 METHOXYPHENYL]BENZAMIDE; N [5 [1 [4 (DIETHYLAMINO)BENZYL]PIPERIDIN 4 YL] 2 METHOXYPHENYL]PYRAZINE 2 CARBOXAMIDE; N [[5 [1 (4 AMINOBENZYL)PIPERIDIN 4 YL] 2 ETHOXY]PHENYL]BENZAMIDE; N [[5 [1 (4 AMINOBENZYL)PIPERIDIN 4 YL] 2 ISOPROPOXY]PHENYL]BENZAMIDE; N [[5 [1 (4 AMINOBENZYL)PIPERIDIN 4 YL] 2 METHOXY]PHENYL]BENZAMIDE; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CALCIUM MOBILIZATION; CALCIUM TRANSPORT; CANCER SIZE; CELL PROLIFERATION; COMPETITIVE INHIBITION; CONTROLLED STUDY; DRUG DESIGN; GRIGNARD REACTION; IN VIVO STUDY; LIGAND BINDING; MALE; MOLECULAR DOCKING; MOLECULAR MODEL; MOUSE; NONHUMAN; PHARMACOPHORE; PROSTATE CANCER; SIGNAL TRANSDUCTION; STRUCTURE ACTIVITY RELATION;

CCR5 ANTAGONIST; PHARMACOPHORE BASED MOLECULAR DESIGN; PROSTATE CANCER;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL PROLIFERATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DESIGN; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; MALE; MICE; MODELS, MOLECULAR; MOLECULAR STRUCTURE; NIH 3T3 CELLS; PROSTATIC NEOPLASMS; RECEPTORS, CCR5; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84884764329     PISSN: 02235234     EISSN: 17683254     Source Type: Journal    
DOI: 10.1016/j.ejmech.2013.09.004     Document Type: Article

References (40)

1. W. Chen, P. Zhan, E. DeClercq, and X. Liu Recent progress in small molecule CCR5 antagonists as potential HIV-1 entry inhibitors Curr. Pharm. Des. 18 2012 100 112
2. K. Kedzierska, S.M. Corwe, S. Turville, and A.L. Cunningham The influence of cytokines, chemokines and their receptors on HIV-1 replication in monocytes and macrophages Rev. Med. Virol. 13 2003 39 56 (Pubitemid 36125504)
3. J. Chinen, and W.T. Shearer Molecular virology and immunology of HIV infection Allergy Clin. Immunol. 110 2002 189 198
4. M. Samson, F. Libert, B.J. Doranz, J. Rucker, C. Liesnard, and C.M. Farber Resistance to HIV-1 infection in caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene Nature 382 1996 722 725
5. G. Opdenakekr, and J. Van Damme Chemotactic factors, passive invasion and metastasis of cancer cells Immunol. Today 13 1992 463 464
6. G. Opdenakker, and J. Van Damme Cytokines and proteases in invasion processes: molecular similarities between inflammation and cancer Cytokine 4 1992 251 258
7. A. Mantovani, B. Bottazzi, F. Colotta, S. Sozzani, and R. Luigi The origin and function of tumor-associated macrophages Immunol. Today 13 1992 265 270
8. M.J. Frederick, and G.L. Clayman Chemokines in cancer Expert Rev. Mol. Med. 3 2001 1 18
9. G.G. Vaday, D.M. Peehl, P.A. Kadam, and D.M. Lawrence Expression of CCL5 (RANTES) and CCR5 in prostate cancer Prostate 66 2005 124 134
10. J. Haung, K. Chen, W. Gong, N.M. Dunlop, and J.M. Wang G-protein coupled chemoattractant receptors and cacner Front. Biosci. 13 2008 3352 3363 (Pubitemid 351594687)
11. E.J. Fernandez, and E. Lolis Structure, function, and inhibition of chemokines Annu. Rev. Pharmacol. Toxicol. 42 2002 469 499 (Pubitemid 34160533)
12. M. Oppermann Chemokine receptor CCR5: insights into structure, function, and regulation Cell. Signal. 16 2004 1201 1210 (Pubitemid 39165449)
13. L.M. Coussens, and Z. Werb Inflammation and cancer Nature 420 2002 860 867 (Pubitemid 36019639)
14. S.C. Robinson, K.A. Scott, J.L. Wilson, R.G. Thompson, A.E.I. Proudfoot, and F.R. Balkwill A chemokine receptor antagonist inhibits experimental breast cancer growth Cancer Res. 63 2003 8360 8365 (Pubitemid 37549490)
15. J.E. Koenig, T. Senge, E.P. Allhoff, and W. Koenig Analysis of the inflammatory network in benign prostate hyperplasia and prostate cancer Prostate 58 2004 121 129 (Pubitemid 38160899)
16. American Cancer Society Cancer Facts and Figures 2012, Atlanta, GA 2012
17. American Cancer Society Prostate Cancer 2012
18. T.B. Dorff, and L.M. Glode Current role of neoadjuvant and adjuvant systemic therapy for high-risk localized prostate cancer Curr. Opin. Urol. 2013 (Epub ahead of print)
19. D.A. Loblaw, C. Walker-Dilks, E. Winquist, S.J. Hotte, and G.C.D.S.G. of C.C.O.P. E.-B. Care, Systemic Therapy in Men with Metastatic Castration-resistant Prostate Cancer: a Systematic Review Clin. Oncol. (R. Coll. Riodiol.) 2013 (Epub ahead of print)
20. H. Jiaoyan, Z. Fangqiang, X. Xiang, H. Hong, H. Wenqiu, and C. Wenhui Tetramethylpyrazine hydrochloride inhibits proliferation and apoptosis in human prostate cancer PC3 cells through Akt signaling pathway J. Third Mil. Med. Univ. 35 2013 105 108
21. C. Zou, X. Li, and R. Jiang The progress of molecular mechanism studies for Chinese traditional medicine on prostate cancer therapy Chin. J. Androl. 26 2012 66 68
22. P. Dorr, M. Westby, S. Dobbs, P. Griffin, B. Irvine, and M. Macartney Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity Antimicrob. Agents Chemother. 49 2005 4721 4732 (Pubitemid 41552605)
23. A. Wood, and D. Armour The discovery of the CCR5 receptor antagonist, UK-427,857, a new agent for the treatment of HIV infection and AIDS Prog. Med. Chem. 43 2005 239 271
24. J.R. Tagat, S.W. McCombie, D. Nazareno, M.A. Labroli, Y. Xiao, and R.W. Steensma Piperazine-based CCR5 antagonists as HIV-1 inhibitors. IV. Discovery of 1-[(4,6-dimethyl-5-pyrimidinyl)carbonyl]-4-[4-[2-methoxy-1(R)-4- (trifluoromethyl)phenyl]ethyl-3(S)-methyl-1-piperazinyl]-4-methylpiperidine (Sch-417690/Sch-D), a potent, highly selective, and orally bioavailable CCR5 antagonist J. Med. Chem. 47 2004 2405 2408 (Pubitemid 38580075)
25. J.M. Strizki, C. Tremblay, S. Xu, L. Wojcik, N. Wagner, and W. Gonsiorek Discovery and characterization of vicriviroc (SCH 417690), a CCR5 antagonist with potent activity against human immunodeficiency virus type 1 Antimicrob. Agents Chemother. 49 2005 4911 4919 (Pubitemid 41782160)
26. A. Palani, and J. Tagat Discovery and development of small-molecule chemokine coreceptor CCR5 antagonists J. Med. Chem. 49 2006 2851 2855
27. M. Baba, O. Nishimura, N. Kanzaki, M. Okamoto, H. Sawada, and Y. Iizawa A small-molecule, nonpeptide CCR5 antagonist with highly potent and selective anti-HIV-1 activity Proc. Natl. Acad. Sci. U. S. A. 96 1999 5698 5703 (Pubitemid 29234681)
28. K. Maeda, H. Nakata, Y. Koh, T. Miyakawa, H. Ogata, and Y. Takaoka Spirodiketopiperazine-based CCR5 inhibitor which preserves CC-chemokine/CCR5 interactions and exerts potent activity against R5 human immunodeficiency virus type 1 in vitro J. Virol. 78 2004 8654 8662 (Pubitemid 39025131)
29. M. Baba, K. Takashima, H. Miyake, N. Kanzaki, K. Teshima, and X. Wang TAK-652 inhibits CCR5-mediated human immunodeficiency virus type 1 infection in vitro and has favorable pharmacokinetics in humans Antimicrob. Agents Chemother. 49 2005 4584 4591 (Pubitemid 41552587)
30. B. Wu, E.Y. Chien, C.D. Mol, G. Fenalti, W. Liu, and V. Katritch Structures of the CXCR4 chemokine GPCR with small-molecule and cyclic peptide antagonists Science 330 2010 1066 1071
31. G. Thoma, F. Nuninger, M. Schaefer, K.G. Akyel, R. Albert, and C. Beerli Orally bioavailable competitive CCR5 antagonists J. Med. Chem. 47 2004 1939 1955 (Pubitemid 38453913)
32. N.E. Kaighn, S. Narayan, Y. Ohnuki, J.F. Lechner, and L.W. Jones Establishment and characterization of a human prostatic carcinoma cell line (PC-3) Invest. Urol. 17 1979 16 23 (Pubitemid 9239413)
33. M. Baba, H. Miyake, M. Okamoto, Y. Iizawa, and K. Okonogi Establishment of a CCR5-expressing T-lymphoblastoid cell line highly susceptible to R5 HIV type 1 AIDS Res. Hum. Retroviruses 16 2000 935 941 (Pubitemid 30436491)
34. B.R. Conklin, Z. Farfel, K.D. Lustig, D. Julius, and H.R. Bourne Substitution of three amino acids switches receptor specificity of Gq to that of Gi alpha Nature 363 1993 274 276 (Pubitemid 23158533)
35. X. Zhang, K.M. Haney, A.C. Richardson, E. Wilson, D.A. Gewirtz, and J.L. Ware Anibamine, a natural product CCR5 antagonist, as a novel lead for the development of anti-prostate cancer agents Bioorg. Med. Chem. Lett. 20 2010 4627 4630
36. M.M. Webber, D. Bello, and S. Quadar Immortalized and tumorgenic adult human prostatic epithelial cell lines: characteristics and applications. Part 2. Tumorigenic cell lines Prostate 30 1997 58 64 (Pubitemid 27053542)
37. D. Yuan, Z. Xiong, C. Zhang, and X. Zhang Inhibitory effects of saponins of spina gledits iae on the proliferation of PC-3 cell Tianjin Med. J. 36 2008 280 282
38. F. Zhang, C.K. Arnatt, K.M. Haney, H.C. Fang, J.E. Bajacon, and A.C. Richardson Structure activity relationship studies of natural product chemokine receptor CCR5 antagonist anibamine toward the development of novel anti prostate cancer agents Eur. J. Med. Chem. 55 2012 395 408
39. E. Borenfreund, and J.A. Puemer Toxicity determined in vitro by morphological alterations and neutral red absorption Toxicol. Lett. 24 1985 119 124 (Pubitemid 15103513)
40. National Toxicology Program (NTP) Interagency Center for the Evaluation of Alternative Toxicological Methods (NICEATM) Test Method Protocol for the BALB/c 3T3 Neutral Red Uptake Cytotoxicity Test A. T. f. B. C. F. a. I. V. V. S., phase III 2003